Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Burkitt lymphoma: staging and response evaluation.

John T Sandlund1

  • 1Department of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA. john.sandlund@stjude.org

British Journal of Haematology
|February 3, 2012
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective randomized trial of interventions for vincristine-related neuropathic pain.

Pediatric blood & cancer·2020
Same author

Whole-joint magnetic resonance imaging to assess osteonecrosis in pediatric patients with acute lymphoblastic lymphoma.

Pediatric blood & cancer·2020
Same author

Integrative genomic analysis of B-lymphoblastic lymphoma with intrachromosomal amplification of chromosome 21.

Pediatric blood & cancer·2020
Same author

The association of mediastinal mass in the formation of thrombi in pediatric patients with non-lymphoblastic lymphomas.

Pediatric blood & cancer·2019
Same author

Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2019
Same author

Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia.

Pediatric blood & cancer·2019

Refinements in staging and response evaluation for pediatric Burkitt lymphoma (BL) have improved outcomes. Novel technologies like positron emission tomography (PET) and minimal residual disease (MRD) assessment require further study for optimal use in children with BL.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Medical Imaging

Background:

  • Treatment outcomes for pediatric Burkitt lymphoma (BL) have improved over 40 years due to advancements in staging and response evaluation.
  • Current staging systems, like the Murphy system (1980), require refinement, especially for extranodal sites (skin, bone).
  • Technological progress has significantly impacted disease detection and response assessment.

Purpose of the Study:

  • To highlight the need for refining staging and response evaluation in pediatric Burkitt lymphoma.
  • To emphasize the role of novel diagnostic technologies in improving assessment.
  • To call for more clinical data on advanced imaging and MRD in pediatric non-Hodgkin lymphoma (NHL).

Main Methods:

  • Review of historical and current staging systems for pediatric BL and NHL.

Related Experiment Videos

  • Discussion of evolving response evaluation modalities from X-rays to PET and MRD.
  • Identification of areas for improvement in staging and response assessment.

    • Main Results:

    • Past staging systems (Ziegler/Magrath, Murphy) have evolved, but opportunities for refinement exist.
    • Functional imaging (PET) and minimal residual disease (MRD) technology offer enhanced sensitivity for disease detection.
    • Significant advancements in imaging technologies (CT, PET) have transformed response evaluation over decades.

    Conclusions:

    • Refined staging and response evaluation are crucial for improving pediatric BL treatment outcomes.
    • Further clinical data is needed on PET and MRD for accurate response assessment in pediatric BL and other NHL subtypes.
    • An international working group is actively refining staging and response evaluation for pediatric NHL.